Q2 2025 · 13F-HR
TYNDALL CAPITAL PARTNERS L Pholdings as filed
Filed 2025-08-14 · accession 0001641172-25-023976
$451,594
Reported value
1
Positions
2025-06-30
Period end
The Brief · TYNDALL CAPITAL PARTNERS L P · Q2 2025
AI · grounded in 13F
TYNDALL CAPITAL PARTNERS L P established a new position in Cyclerion Therapeutics Inc CYCN valued at $451,594. This single trade accounts for the fund's total assets under management of $451,594. The fund holds no other positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 23255M204 | CYCN | CYCLERION THERAPEUTICS INC | $451,594 | 100.0% | 155,187 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.